Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Definium Therapeutics, Inc. - Common Shares (NQ:DFTX)

38.41 +2.24 (+6.19%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,994,377
Open	35.92
Bid (Size)	38.25 (100)
Ask (Size)	38.80 (100)
Prev. Close	36.17
Today's Range	35.51 - 39.10
52wk Range	14.62 - 49.70
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Definium Therapeutics Announces New Employee Inducement Grants

Today 16:01 EDT

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression ↗

September 24, 2026

Definium Therapeutics (NASDAQ:DFTX) Chief Medical Officer Dan Karlin said the company’s recent Phase III results for DT120 showed statistically significant improvements in generalized anxiety disorder,...

Via MarketBeat

Performance

YTD	+149.7%	+149.7%
1 Month	-6.3%	-6.3%
3 Month	-17.5%	-17.5%
6 Month	+119.5%	+119.5%
1 Year	+149.7%	+149.7%

More News

Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study ↗

September 19, 2026

Via MarketBeat

Definium Therapeutics (NASDAQ:DFTX) Slides After Q2 Loss Misses Estimates on Warrant Charge ↗

August 06, 2026

Via Chartmill

Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder

September 14, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

September 14, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

September 13, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026

September 10, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results

September 08, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

August 31, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

August 26, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

August 17, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics’ DT120 Meets Phase III Goals in GAD Study ↗

August 13, 2026

Via MarketBeat

Wondering what's happening in today's pre-market session? ↗

August 12, 2026

Via Chartmill

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

August 12, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Q2 Earnings Call Highlights ↗

August 06, 2026

Via MarketBeat

Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 06, 2026

From Definium Therapeutics, Inc.

Via Business Wire

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout

August 05, 2026

From USA News Group

Via GlobeNewswire

Definium Therapeutics Announces New Employee Inducement Grants

August 03, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

July 30, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

July 20, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology

July 16, 2026

From Definium Therapeutics, Inc.

Via Business Wire

New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)

July 14, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Definium Therapeutics Announces New Employee Inducement Grants

July 06, 2026

From Definium Therapeutics, Inc.

Via Business Wire

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

June 30, 2026

Via FinancialNewsMedia

Frequently Asked Questions

Is Definium Therapeutics, Inc. - Common Shares publicly traded?

Yes, Definium Therapeutics, Inc. - Common Shares is publicly traded.

What exchange does Definium Therapeutics, Inc. - Common Shares trade on?

Definium Therapeutics, Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Definium Therapeutics, Inc. - Common Shares?

The ticker symbol for Definium Therapeutics, Inc. - Common Shares is DFTX on the Nasdaq Stock Market

What is the current price of Definium Therapeutics, Inc. - Common Shares?

The current price of Definium Therapeutics, Inc. - Common Shares is 38.41

When was Definium Therapeutics, Inc. - Common Shares last traded?

The last trade of Definium Therapeutics, Inc. - Common Shares was at 09/28/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.